INmune Bio (INMB) Q1 2026 Earnings
INMB·Reported May 7, 2026·After market close
Diluted EPS came in at $-0.20 (+53.5% YoY), beat the $-0.24 consensus by $0.04.
Diluted EPS
$-0.20beat by $0.04
Consensus: $-0.24
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about INmune Bio's Q1 2026 earnings report.
INmune Bio (INMB) reported Q1 2026 earnings on May 7, 2026 after market close.
INmune Bio reported diluted EPS of $-0.20 for Q1 2026.
EPS beat the consensus estimate of $-0.24 by $0.04.
Compared to the same quarter a year prior, diluted EPS grew 53.5% from $-0.43.
You can read the 8-K earnings release (0001213900-26-052231) and the 10-Q periodic report (0001213900-26-053338) directly on SEC EDGAR. The filing index links above go to sec.gov.